[Effectiveness of combined therapy in patients with clear cell carcinoma of the kidney].
The paper presents preliminary results of a combined therapy consisted of INF-alpha, TNF-alpha and Vinblastine administrated to 12 patients with advanced clear cell carcinoma of kidney. All patients accrued into this protocol underwent unsuccessful conventional oncological treatment. In 2 subjects the treatment was interrupted because of acute adverse events during the first course of the combined therapy. In the remaining group: 3 patients showed long term partial remission (PR) (follow up time up to 9.5 months) and 4 patients responded with minor/stable disease. The disease progression was observed in 2 patients.
Muc-Wierzgoń
M
M
V Katedry i Kliniki Chorób Wewnetrznych Slaskiej Akademii Medycznej.
Ziółko
E
E
Madej
K
K
D018262:Adenocarcinoma, Clear Cell / Q000188:drug therapy*; D000368:Aged; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000009:adverse effects / Q000627:therapeutic use*; D018450:Disease Progression; D005260:Female; D006801:Humans; D016898:Interferon-alpha / Q000008:administration & dosage; D007680:Kidney Neoplasms / Q000188:drug therapy*; D008297:Male; D008875:Middle Aged; D012074:Remission Induction; D014409:Tumor Necrosis Factor-alpha / Q000008:administration & dosage; D014747:Vinblastine / Q000008:administration & dosage
D016898:Interferon-alpha; D014409:Tumor Necrosis Factor-alpha; D014747:Vinblastine